Ambrx Biopharma Inc.

About Ambrx Biopharma Inc.

Ambrx is a pioneer and leader in next-generation Antibody Drug Conjugates (ADCs), focusing on precision biologics innovation. The company is dedicated to advancing enhanced antibody-drug conjugates, immuno-oncology conjugates, and bispecific candidates as potential treatments for cancer, utilizing their proprietary Expanded Genetic Code Technology Platform.

Products & Services

ARX788:An antibody-drug conjugate candidate for cancer treatment.

ARX622:A candidate with TLR7 agonist properties, presented at PEGS Europe.

Enhanced Antibody Drug Conjugates:Next-generation ADCs designed for highly stable, site-specific conjugation.

Immuno-Oncology Conjugates:Candidates aimed at enhancing immune responses against cancer.

Bispecific Candidates:Therapies targeting multiple cancer pathways.

Specialties

Next-Generation Antibody Drug Conjugates (ADCs) Expanded Genetic Code Technology Precision Biologics Immuno-Oncology Conjugates Bispecific Therapies Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 75000000 MR: - FA: 75 million FAN: 75000000	D: 2023-06-28 FD: 2023-06-28	-
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2023-05-24 FD: 2023-05-24	1 investors
3	RT: ATM Program T: - FT: ATM Program	A: 78000000 MR: - FA: approximately $78 million FAN: 78000000	D: 2023-03-13 FD: 2023-03-13	1 investors

Registered Direct Offering Latest

2023-06-28

$75.0M

Registered Direct Offering 2023-05-24

$75.0M

ATM Program 2023-03-13

$78.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Renu Vaish

Chief Regulatory Officer

S

Sandra Aung, Ph.D.

Chief Clinical Officer

S

Sonja Nelson

Chief Financial Officer

Y

Ying Buechler, Ph.D.

Chief Technology Officer

S

Shawn Zhang, Ph.D.

Chief Scientific Officer and General Manager China

View 2 more team members with Pro

Unlock Full Team Directory

Recent News